Shilpa Medicare Ltd, Ramkrishna Forgings Ltd, Arman Financial Services Ltd and Jubilant Pharmova Ltd are among the other losers in the BSE s A group today, 18 February 2021.
Shilpa Medicare Ltd, Ramkrishna Forgings Ltd, Arman Financial Services Ltd and Jubilant Pharmova Ltd are among the other losers in the BSE s A group today, 18 February 2021.
Clariant Chemicals (India) Ltd lost 9.19% to Rs 410.95 at 14:48 IST.The stock was the biggest loser in the BSE s A group.On the BSE, 28015 shares were traded on the counter so far as against the average daily volumes of 25346 shares in the past one month.
Shilpa Medicare Ltd tumbled 9.04% to Rs 387.6. The stock was the second biggest loser in A group.On the BSE, 1.44 lakh shares were traded on the counter so far as against the average daily volumes of 11786 shares in the past one month.
The American Association for Long-Term Care Insurance (AALTCI) has announced a special effort to help consumers facing problems filing or receiving long-term care insurance claim benefits. The nation s long-term care insurance companies do an excellent job of helping policyholders with claims questions and filing support but from time to time people call us with issues or problems, explains Jesse Slome, director of the long-term care insurance organization. Typically the insurance agent who initially sold the policy is retired or a claim they believe should qualify for benefits is declined by the insurer.
To help consumers with claims questions or issues the Association will partner with Family Solutions For Care. The long-term care insurance claims assistance specialists have secured over $175 million in long-term care insurance benefits for families.
DGAP-News: Immun .
DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
vom 18.02.2021, 12:30 Uhr
Bild: pixabay.com
DGAP-News: Immunic, Inc. / Key word(s): Study results
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
18.02.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
- Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -
Phase 2/3 trial will enroll approximately 4,000 healthy pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, U.K., and SpainFirst participants dosed in the U.S. Women